pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

Vaccination 105

Vaccination Vaccine Development Hormones 105

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. ER is the primary driver of hormone receptor (HR) positive breast cancer, which is the most common breast cancer subtype.

Protein 52

Protein Development HR Hormones 52

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Genetics 115

Genetics Hormones Genomics Genome 115

Pharmaceutical Technology

MAY 31, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). It is administered as an intravenous infusion. It is developed based on sympress platform technology.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. However, the similarity between the two proteins is not great enough for anti-spike antibodies to cross-react with placental syncytin-1.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

XTalks

NOVEMBER 5, 2024

a clinical-stage biotech company focused on pioneering therapies based on G protein-coupled receptors (GPCRs), recently completed its initial public offering (IPO), marking a significant milestone for the South San Francisco-based firm. SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

The Pharma Data

DECEMBER 9, 2020

9, 2020 — More women with early-stage breast cancer may be able to safely skip chemotherapy after having surgery, according to initial results from a major clinical trial. The trial, conducted in nine countries, found that adding chemotherapy to hormone-blocking drugs brought no added benefit to a particular group of patients.

Hormones 52

Hormones Trials Medicine Research 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA Now Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer. KEYTRUDA Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer.

Hormones 52

Hormones HR Trials Protein 52

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

MARCH 13, 2024

XTALKS WEBINAR: Addressing Ophthalmology Clinical Trial Design and Effective Data Monitoring Committee Strategies On-Demand: Thursday, February 8, 2024 Register for this free webinar gain insights into statistical data strategies for ophthalmology clinical trials and learn best practices for establishing and reporting ophthalmic data.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?

HR 52

HR Hormones FDA Approval Antibody 52

Find Me Cure

OCTOBER 13, 2019

There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials. Rosenberg, M.D.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception : Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. 07.27.2022. 07.19.2022.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

APRIL 7, 2023

2-5 Philipp Harter, Director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: “DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer.

Trials 40

Trials DNA Medicine Development 40

The Pharma Data

APRIL 27, 2022

6 Currently chemotherapy remains the only treatment option for patients with HR-positive tumours following progression on endocrine (hormone) therapy. The FDA granted the BTD based on data from the pivotal DESTINY-Breast04 Phase III trial which reported positive high-level results in February 2022.

HR 52

HR Trials Protein Medicine 52

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Eli Lilly backed Terns Pharmaceuticals now has two NASH candidates in clinical trials. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. However, due to specific reasons, the TTR protein begins to misfold and aggregate as fibrils, a process known as amyloidosis of Transthyretin (ATTR). Liver Transplantation.

Protein 52

Protein Gene Silencing Marketing Gene 52

The Pharma Data

MARCH 22, 2021

VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021. Results from the VISION trial will be presented at an upcoming medical meeting and included in US and EU regulatory submissions.

Hormones 52

Hormones Gene Therapy Medicine Trials 52

Velocity Clinical Research

JUNE 27, 2023

Trial results were presented at the ADA sessions and published in NEJM. Dr. Frias is the lead author for Eli Lily’s Phase 2 trial for orforglipron for type 2 diabetes. Trial results were presented at the ADA sessions and published in The Lancet. Trial results were presented at the ADA sessions and published in The Lancet.

Insulin 52

Insulin Trials Hormones Clinical Trials 52

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. It works by targeting a protein called B-lymphocyte stimulator (BLyS) that is overproduced in people with lupus and contributes to an overactive immune system.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

AUGUST 11, 2020

The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. PRINCETON, N.J.–(

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 17, 2021

The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 The monarchE trial is ongoing and patients will continue to be followed to assess safety, PROs and other endpoints.

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. The partial piece of the spike protein cannot cause COVID-19 disease.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

The Pharma Data

NOVEMBER 19, 2020

Researchers with the German Center for Neurodegenerative Diseases (DZNE) working in mice found that Alzheimer’s began much earlier with a fatal chain reaction that results in misfolded beta-amyloid proteins that get out of control and “literally floods the brain.” It is a hormone. Melatonin is produced by the body in darkness.

Research 52

Research Protein Nurses Immune Response 52

Roots Analysis

AUGUST 31, 2023

Further, the expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. There are various regulatory proteins or transcription factors that are responsible for affecting the transcription rate. When activator binds to the operon, it either speeds up or permits gene expression.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Pfizer

JANUARY 27, 2023

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. No dosage adjustment is needed in patients with mild renal impairment.

Research 112

Research Vaccination Vaccine Drugs 112

XTalks

JUNE 10, 2024

Efruxifermin is a novel Fc-FGF21 fusion protein designed to emulate the activity of native FGF21, an endogenous hormone that regulates metabolism and alleviates cellular stress.

Insulin 52

Insulin Life Science Regulation Hormones 52

XTalks

MARCH 22, 2021

Maverick’s COBRA platform is used to engineer protein-based therapies that target T cells in the tumor microenvironment to trigger their activation. The therapies are designed to induce T cell-mediated killing specifically at the tumor site while sparing healthy cells and tissue.

Life Science 110

Life Science Development Marketing Gene Expression 110

The Pharma Data

JANUARY 10, 2021

We expect to further advance our late stage endocrinology pipeline with the anticipated approval and launch in the United States and the approval in Europe of TransCon hGH for pediatric growth hormone deficiency, and to obtain phase 3 results for TransCon PTH in adult hypoparathyroidism. Pipeline Updates. •.

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 27, 2021

We look forward to working with Eurofins Discovery to bring this treatment to patients as quickly as possible as we prepare for our IND and trials,” said BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian.

In-Vitro 52

In-Vitro Containment Drugs Production 52

XTalks

DECEMBER 22, 2021

RNA, and its protein-generating form messenger RNA (mRNA) discovered in 1961 , has quickly transitioned from being an obscure, finicky molecule that is difficult to work with, to becoming a significant cornerstone of therapeutic innovation in pharma and biotech. The RNA Revolution: From mRNA Vaccines to RNA Editing.

Life Science 98

Life Science RNA Vaccination Vaccine 98

The Pharma Data

SEPTEMBER 16, 2020

Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme.

HR 52

HR Medicine Hormones Trials 52

Pfizer

DECEMBER 20, 2022

Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide.

Drugs 69

Drugs Licensing Licensing Containment 69